دورية أكاديمية
أعرض في EDS

Trends in rifampicin resistance among patients with presumptive TB in the pre-COVID and COVID-era.

التفاصيل البيبلوغرافية
العنوان: Trends in rifampicin resistance among patients with presumptive TB in the pre-COVID and COVID-era.
المؤلفون: Alao MA; Department of Paediatrics, Bowen University Teaching Hospital, Box 15, Ogbomoso, Oyo State, Nigeria.; Department of Paediatrics, College of Medicine University of Ibadan & University College Hospital, Ibadan, Oyo State, Nigeria., Ibrahim OR; Department of Paediatrics, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria., Akinboro AO; Ladoke Akintola University of Technology Ogbomoso, Ogbomoso, Oyo State, Nigeria., Oladipo TS; Department of Medical Microbiology, Bowen University Teaching Hospital Ogbomoso, Oyo State, Nigeria., Chan YH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Ogunbosi BO; Department of Paediatrics, College of Medicine University of Ibadan & University College Hospital, Ibadan, Oyo State, Nigeria.
المصدر: Journal of clinical tuberculosis and other mycobacterial diseases [J Clin Tuberc Other Mycobact Dis] 2022 Dec; Vol. 29, pp. 100335. Date of Electronic Publication: 2022 Oct 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101682877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-5794 (Electronic) Linking ISSN: 24055794 NLM ISO Abbreviation: J Clin Tuberc Other Mycobact Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Elsevier Ltd., [2015]-
مستخلص: Background: The COVID 19 pandemic has had its impact on tuberculosis notification, incidence, and management, particularly in the context of rifampicin-resistant TB. We set out to determine the trends in rifampicin resistant tuberculosis between the pre-COVID and COVID era in a resource-constrained setting.
Methods: This was a retrospective review of single early morning sputum from presumed tuberculosis between January 2016 and May 2022 in a regional TB referral and treatment centre in South-western, Nigeria. We used a molecular beacon to detect Mycobacterium tuberculosis (MTB) and mutations in the rpo B gene using a real-time polymerase chain reaction (PCR).
Results: We analyzed 19,892 of 20,589 presumptive TB with complete data. Most subjects were in the age group 18-45 years (10,594; 53.3 %) and were males (11,492; 57.8 %). Of the 19,892 presumptive TB, 4,526 (22.8 %) were in pre-COVID-19 era (Jan 2016-December 2019) and 15,366 (77.2 %) cases were in COVID-19 era (Jan 2020-May 2022). The MTB notification declined during the COVID-19 era compared with the pre-COVID-19 era (10.5 % vs 12.9 %, p < 0.001). The annual prevalence of MTB rose from 5.6 % (2016) to a peak of 23.2 % in 2019 (pre-COVID-19 era), followed by a decline to 12.8 % in 2020 and 8.6 % in 2022 (COVID-19 era), p = <0.001). The overall incidence of RR-TB was 3.8 %. The incidence of RR was higher during pre-COVID-19 than the COVID-19 era, 9.5 % vs 2.5 %, p = <0.001. The incidence of RR-TB declined substantially from 28.0 % in 2016 to 1.6 % in 2021 but rose exponentially to 5.4 % in 2022. After controlling for confounders, only the pre-COVID-19 status was associated with increased odds for RR (adjusted odds ratio 3.3, 95 % confidence interval, 2.049, 5.421).
Conclusion: This study found a progressive decline in MTB notification since the COVID-19 pandemic's outbreak. Furthermore, RR-TB notification decreased gradually in the pre-COVID-19 era, with a resurgence in 2022. In the era of COVID-19, there is an urgent need to increase intervention efforts in order to halt the decline in MTB detection rates and the resurgence of RR-TB.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2022 The Author(s).)
References: J Anaesthesiol Clin Pharmacol. 2018 Jan-Mar;34(1):84-93. (PMID: 29643629)
Trop Med Infect Dis. 2020 Jul 24;5(3):. (PMID: 32722014)
J Clin Tuberc Other Mycobact Dis. 2022 May 17;28:100319. (PMID: 35599722)
Front Public Health. 2022 Apr 04;10:820642. (PMID: 35444988)
Front Public Health. 2021 Jan 15;8:582932. (PMID: 33520910)
PLoS One. 2020 Oct 29;15(10):e0239225. (PMID: 33119601)
Public Health Action. 2020 Dec 21;10(4):157-162. (PMID: 33437681)
Eur Respir J. 2020 Oct 22;56(4):. (PMID: 32978310)
Nat Med. 2022 Jun;28(6):1314-1324. (PMID: 35288697)
Eur J Med Res. 2021 Jul 3;26(1):67. (PMID: 34217366)
Eur Respir J. 2020 Aug 13;56(2):. (PMID: 32513784)
Lancet Infect Dis. 2020 Nov;20(11):1240-1241. (PMID: 33038941)
Lancet Respir Med. 2020 Jun;8(6):536-538. (PMID: 32220280)
Int J Infect Dis. 2021 Dec;113 Suppl 1:S88-S90. (PMID: 33744479)
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141. (PMID: 32673577)
BMC Infect Dis. 2021 Oct 2;21(1):1032. (PMID: 34600485)
Eur Respir J. 2021 Nov 11;58(5):. (PMID: 34446465)
Int J Infect Dis. 2022 Mar 20;:. (PMID: 35321845)
فهرسة مساهمة: Keywords: COVID-19; Nigeria; Pre-COVID; Rifampicin-resistant-TB; Tuberculosis
تواريخ الأحداث: Date Created: 20221107 Latest Revision: 20221115
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9617635
DOI: 10.1016/j.jctube.2022.100335
PMID: 36337167
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-5794
DOI:10.1016/j.jctube.2022.100335